Welcome to our dedicated page for Microvision SEC filings (Ticker: MVIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to MicroVision, Inc. (NASDAQ: MVIS) SEC filings, offering a centralized view of the company’s regulatory disclosures. Through these documents, investors can review how MicroVision reports on its lidar hardware and perception software business, its activities in automotive, industrial, and defense-related markets, and its corporate governance and financing arrangements.
Key filings for MicroVision include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and financial results. These reports are particularly relevant for understanding MicroVision’s investment in solid-state lidar technologies, its focus on ADAS and autonomous driving, and its efforts in industrial automation and defense tech. Current reports on Form 8-K provide timely updates on material events, such as leadership changes, executive compensation arrangements, board appointments, and the announcement of quarterly results.
MicroVision’s filings also document corporate actions like the appointment of a new Chief Executive Officer, the designation of an Executive Vice Chair, changes in board composition, and transitions in the Chief Financial Officer role. These disclosures help investors track how the company’s leadership and governance structure evolve alongside its strategic focus on autonomy and mobility.
On Stock Titan, MicroVision’s SEC documents are updated in near real time as they are posted to EDGAR. AI-powered summaries assist readers by highlighting the main points in lengthy filings, including key business updates, segment information where provided, and notable risk or governance items. Users can quickly scan 10-K and 10-Q reports, review 8-K announcements about material events, and access other filings while relying on AI-generated explanations to navigate complex regulatory language more efficiently.
MicroVision interim CFO Stephen Hrynewich reported routine equity award activity. On February 5, 2026, 4,800 vested restricted stock units converted into the same number of shares of common stock at $0.00 per share, increasing his direct holdings to 160,933 shares.
On February 6, 2026, the issuer completed a tax withholding, nondiscretionary sell-to-cover transaction for 1,477 common shares at a weighted average price of $0.704 per share, leaving Hrynewich with 159,456 directly owned shares.
MicroVision, Inc. completed its previously announced acquisition of certain assets related to Luminar Technologies, Inc.’s lidar sensor business. On February 3, 2026, MicroVision closed the transaction and paid Luminar $33,000,000 in cash, funded entirely from MicroVision’s cash on hand.
The company plans to provide any required financial statements and pro forma financial information for the acquired assets in a later amendment, to be filed no later than 71 calendar days after this report was required to be filed.
MicroVision, Inc. entered into an Asset Purchase Agreement to acquire certain lidar sensor business assets from Luminar Technologies, Inc., including intellectual property and inventory related to Luminar’s Iris and Halo sensors. The acquisition excludes Luminar’s photonics business historically conducted by Luminar Semiconductor, Inc.
MicroVision agreed to pay a purchase price of $33,000,000, subject to potential adjustment under the agreement, and expects to fund the acquisition with current cash on hand. MicroVision was selected as the winning bidder in a competitive auction conducted under Section 363 of the U.S. Bankruptcy Code, and the U.S. Bankruptcy Court approved the agreement and related transactions on January 27, 2026. The obligations of both parties remain subject to customary closing conditions.
MicroVision, Inc. reported that it received a deficiency notice from Nasdaq on January 12, 2026 because its common stock failed to meet the minimum bid price requirement of $1 per share for the last 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1). The notice does not immediately affect the listing or trading of its shares, and the company remains in compliance with all other Nasdaq continued listing standards. MicroVision has 180 days from the notice date to regain compliance and is evaluating available options, while its business operations, SEC reporting, and contractual obligations continue unchanged.
MicroVision, Inc. interim CFO Stephen Hrynewich reported routine equity compensation activity. On January 5, 2026, 4,800 restricted stock units vested and were distributed to him as shares of common stock on a unit-for-share basis at $0.00 per share. These RSUs simultaneously ceased to exist as a derivative position.
On January 6, 2026, the issuer completed a withholding tax-related, nondiscretionary sell-to-cover of 1,573 shares of common stock at a price of $0.9185 per share under the award agreement. After these transactions, Hrynewich directly beneficially owned 156,133 shares of MicroVision common stock.
MicroVision interim CFO reports equity holdings as a company insider. Interim CFO Stephen Hrynewich beneficially owns 152,906 shares of MicroVision common stock directly. In addition, he holds derivative securities in the form of restricted stock units (RSUs) tied to MicroVision common stock.
One RSU grant for 30,000 shares was granted on 11/20/2025 and is scheduled to vest 16% on 1/5/2026, 2/5/2026, 3/5/2026, 4/6/2026, and 5/5/2026, and 20% on 6/5/2026, subject to his continued employment on each vesting date. A separate RSU award for 25,000 shares vests on 09/08/2026. Each RSU represents a contingent right to receive one share of MicroVision common stock at an exercise price of $0.00.
MicroVision, Inc. announced that Chief Financial Officer Anubhav Verma resigned from his position, effective no later than December 31, 2025. The company stated that his resignation did not result from any disagreement regarding financial statements, internal controls, operations, policies, or practices.
To support continuity, the Board appointed Stephen Hrynewich, currently Vice President, Global Finance & Operations, to serve as Interim Chief Financial Officer as of the effective date. Hrynewich was also designated as the company’s principal financial officer and principal accounting officer. MicroVision has begun a search to identify a permanent Chief Financial Officer.
MicroVision (MVIS) CFO equity activity: Chief Financial Officer Anubhav Verma reported the vesting of restricted stock units and related share activity. On 11/17/2025, 16,765 restricted stock units vested and were converted into the same number of common shares at an exercise price of $0.00. On 11/18/2025, 4,225 common shares were disposed of at $0.941 per share in a tax withholding "sell-to-cover" transaction completed by the company under the award terms.
Following these transactions, Verma beneficially owned 499,438 shares of MicroVision common stock in direct ownership, and no restricted stock units remained from this specific award. The filing notes that the RSUs were distributed on a one-for-one share basis and that the tax sale was nondiscretionary, carried out in accordance with the award agreement.
MicroVision, Inc. filed a current report to inform investors that it has released its third quarter 2025 financial results. On November 11, 2025, the company issued a press release detailing these results, which is attached to the report as Exhibit 99.1 and incorporated by reference. The company notes that the information is being furnished rather than filed under securities laws, which affects how it is treated for legal liability purposes but still makes the earnings information available to the market.
MicroVision, Inc. reporting person Simon Biddiscombe, an Executive Vice Chair and Director, received a grant of 241,000 restricted stock units (RSUs) on 10/01/2025. The RSUs convert unit-for-share at vesting with no cash payment required, and are scheduled to vest in full on 10/01/2026 provided the reporting person continues service through that date. The Form 4 discloses the transaction date as 10/01/2025 and the filing was signed by an attorney-in-fact on 10/02/2025. The report records direct beneficial ownership of 0 common shares following the grant because the RSUs have not yet vested.